Parenteral Drugs (India) Limited

PDPL

INE904D01019

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 03:30:51 21/08/2023 pm IST			5-day change	1st Jan Change
3.39 ^INR	+4.63%		-.--%	-.--%

2023	PSBs Reportedly Shelve Deal to Sell Drug Company Loans to NARCL	CI
2023	NARCL Reportedly Offers to Buy INR 11,000 million Loans of Parenteral Drugs	CI

Parenteral Drugs Limited Announces Appointment of Mr. Sandeep Vyas as an Additional and Independent Director

November 14, 2016 at 03:54 pm IST

Parenteral Drugs (India) Limited announced that the Board of Directors of the Company at their meeting held on November 14, 2016 had considered & approved the appointment of Mr. Sandeep Vyas as an additional and Independent director on the Board of the Company.

Latest news about Parenteral Drugs (India) Limited

PSBs Reportedly Shelve Deal to Sell Drug Company Loans to NARCL	04/23/04	CI
NARCL Reportedly Offers to Buy INR 11,000 million Loans of Parenteral Drugs	11/23/11	CI
Parenteral Drugs Limited Announces Resignation of Pooja Choukse as Company Secretary	10/22/10	CI
Parenteral Drugs Limited Announces Director Changes	09/22/09	CI
Parenteral Drugs Limited Appoints Smt. Chhaya Gupta as an Independent Director	01/22/01	CI
Parenteral Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	14/22/14	CI
Parenteral Drugs Limited Announces Change in Directorate	02/22/02	CI
Parenteral Drugs Limited Announces Executive Changes	02/22/02	CI
Parenteral Drugs Limited Announces Change in Terms of One Time Loan Settlement Proposal	06/22/06	CI
Parenteral Drugs Limited Announces Resignation of Suruchi Maheshwari as Company Secretary and Compliance Officer	01/22/01	CI
Parenteral Drugs Limited Announces Resignation of Deepali Garhewal as Director	30/21/30	CI
Parenteral Drugs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	12/21/12	CI
Parenteral Drugs India Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	10/21/10	CI
Parenteral Drugs India Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	30/21/30	CI
Parenteral Drugs Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	12/21/12	CI
Parenteral Drugs Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020	10/20/10	CI
Parenteral Drugs India Limited Reports Earnings Results for the First Quarter Ended June 30, 2020	25/20/25	CI
Parenteral Drugs India Limited Reports Earnings Results for the Third Quarter Ended December 31, 2019	12/20/12	CI
Parenteral Drugs Limited Reports Unaudited Standalone and Consolidated Earnings Results for the Second Quarter and Six Months Ended September 30, 2019	13/19/13	CI
Parenteral Drugs India Limited Reports Earnings Results for the First Quarter Ended June 30, 2019	06/19/06	CI
Parenteral Drugs Limited Announces Disqualification Vinod Kumar Gupta as Director	11/19/11	CI
Parenteral Drugs India Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2019	30/19/30	CI
Parenteral Drugs Limited Appoints Vinod Kumar Gupta as Chief Financial Officer	23/19/23	CI
Parenteral Drugs Limited Announces the Resignation of Mr. Balkrishna Vinayak Chaubal from the Post of Nominee Director	20/19/20	CI
Parenteral Drugs Limited Announces Cessation of Vinod Kumar Gupta as Managing Director	27/19/27	CI

Chart Parenteral Drugs (India) Limited

Duration

Period

More charts

Company Profile

Parenteral Drugs (India) Limited is engaged in the manufacturing of pharmaceutical products. It also manufactures intravenous (IV) infusion, inhalation, and veterinary infusion. It offers products in various categories, including IV fluids, oncology, anesthesia and exports. Its IV Fluids include Carbohydrated and Electrolytes, such as Dextrose IP 5%, 10%, 20%, Dextrose IP 25% , and Ringer Lactate IP; Diuretics, such as Mannitol 10%, 20% and Manidex (Mannitol 10% with Glycerine 10%); Dialysis and Irrigation Solution, such as Peritoneal Dialysis Solution with 1.7% Dextrose and 1.5% Glycine; Anti-infective and Anti-fungal, such as Ciprofloxacin 200mg and Metronidazole 500mg and others , such as Tamolgan (Paracetamol 1000mg) and PD-Invert (10% Invert Sugar). Its Oncology product mix includes 5 FU-PAR and BAZIPAR. Its Anesthesia product mix includes Sevoplan (Sevoflurane 100/250ml) and Isoplan (Isoflurane 100/250ml).

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PARENTERAL DRUGS (INDIA) LIMITED	-.--%	12.11L
ELI LILLY AND COMPANY	+55.19%	81TCr
NOVO NORDISK A/S	+47.26%	65TCr
JOHNSON & JOHNSON	-6.09%	35TCr
MERCK & CO., INC.	+21.92%	34TCr
ASTRAZENECA PLC	+18.40%	25TCr
ROCHE HOLDING AG	+3.64%	23TCr
NOVARTIS AG	+12.98%	22TCr
AMGEN INC.	+10.86%	17TCr
PFIZER, INC.	-2.78%	16TCr

Other Pharmaceuticals

Parenteral Drugs (India) Limited

Equities

PDPL

INE904D01019

Pharmaceuticals

Parenteral Drugs Limited Announces Appointment of Mr. Sandeep Vyas as an Additional and Independent Director

Latest news about Parenteral Drugs (India) Limited

Chart Parenteral Drugs (India) Limited

Company Profile

Sector Other Pharmaceuticals